Muscle spasticity refers to a condition marked by stiffness or contraction of muscles. Conditions like cerebral palsy or multiple sclerosis can cause muscle spasticity. Products like muscle relaxants, analgesics, and physical therapy are commonly used to treat muscle spasticity. Physical therapy helps in relaxation of muscles through massage and exercises. It has gained increased prominence in recent years due to its minimal side effects compared to alternatives.
The global Muscle Spasticity Market is estimated to be valued at US$ 4942.44 Mn in 2023 and is expected to exhibit a CAGR of 7.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends driving growth in the muscle spasticity market is increased adoption of physical therapy. Physical therapy involves the use of techniques like massage, range of motion and strengthening exercises to reduce muscle tone and relax contracted muscles. It helps improve muscle flexibility, gait and mobility of patients. Compared to drugs, physical therapy poses minimal risks of side effects. Moreover, some patients may not respond well to medications but physical therapy can still help reduce their symptoms. As such, more healthcare practitioners are now recommending combining drug therapy with physical therapy programs for long term management of muscle spasticity. This increasing reliance on physical therapy as an important treatment approach will favor revenues in the overall muscle spasticity market during the forecast period.
Segment Analysis
The global muscle spasticity market has mainly three segments - by treatment type, symptoms type, and end user. The treatment type segment of botulinum toxins is dominating the market. Botulinum toxins are protein complexes produced by Clostridium botulinum bacteria. Botulinum toxins are administered by injection into specific muscles and help reduce muscle movement for a period of 3 to 4 months, thus providing relief from spasticity symptoms. The long lasting effect and minimal side effects have made it the treatment of choice for muscle spasticity.
Key Takeaways
The Global Muscle Spasticity Market Size is expected to witness high growth over the forecast period of 2023 to 2030. The global Muscle Spasticity Market is estimated to be valued at US$ 4942.44 Mn in 2023 and is expected to exhibit a CAGR of 7.5% over the forecast period 2023 to 2030.
Regional Analysis
Europe region currently dominates the global muscle spasticity market with the highest market share. This is due to the high prevalence of nervous system disorders such as cerebral palsy and multiple sclerosis leading to muscle spasticity in countries like the UK, Germany, and France. Moreover, the early treatment adoption and strong reimbursement policies are fueling the market growth in the European region. The Asia Pacific region is expected to be the fastest growing market during the forecast period owing to rising incidence of nervous system disorders, growing medical tourism, and improving healthcare infrastructure in countries like China and India.
Key Players
Key players operating in the muscle spasticity market are Blackmores Limited, Vitaco Holdings Limited, Integria Healthcare, Bioglan, Deep Blue Health (NZ) Co. Limited, Phytomed, NZ Herbals, and Sanderson. Blackmores Limited and Vitaco Holdings Limited are leading players in the nutrition supplement segment for managing muscle spasticity symptoms. Integria Healthcare and Bioglan are pioneers in developing innovative nerve muscle relaxation products. Deep Blue Health (NZ) Co. Limited, Phytomed and NZ Herbals offer herbal and plant-based formulations for nerve and muscle relaxation in cases of spasticity. Sanderson has a wide portfolio of drugs and therapeutics targeting the underlying causes and reducing symptoms of spasticity.
Get more insights on this topic:
https://www.dailyprbulletin.com/muscle-spasticity-market-insights/
New York, NY 08 May 2021: The global cannabis pharmaceuticals market is expected to reach USD 5.72 billion by 2027, according to a new study by Polaris Market Research.
The report “Cannabis Pharmaceuticals Market Share, Size, Trends, Industry Analysis Report, By Product (Epidiolex, Marinol, Cesamet and Sativex); By Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies), By Regions; Segment Forecast, 2020 – 2027” gives a detailed insight into current market dynamics and provides analysis on future market growth.Favorable legislation in the market, policies across developed economies, and investments in the research and development for cannabis-infused drugs are the key factors responsible for the market growth.
Moreover, technological innovation to decide the accurate dose of cannabis-infused drugs with cutting edge delivery methods to ensure therapeutic and psychoactive events, to contain drug abuse among adults also favoring market growth for cannabis pharmaceuticals.
Request For Sample Copy @ https://www.polarismarketresearch.com/industry-analysis/cannabis-pharmaceuticals-market/request-for-sample The global market for cannabis pharmaceuticals is fragmented based on product, distribution channel, and region.
In terms of product, the market is segmented into Epidiolex, Marinol, Cesamet, and Sativex.
Based on distribution channel, the cannabis pharmaceuticals industry is further bifurcated into hospital, online, and retail pharmacies.
The global cannabis pharmaceuticals market is expected to reach USD 5.72 billion by 2027, according to a new study by Polaris Market Research.
The report “Cannabis Pharmaceuticals Market Share, Size, Trends, Industry Analysis Report, By Product (Epidiolex, Marinol, Cesamet and Sativex); By Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies), By Regions; Segment Forecast, 2020 – 2027” gives a detailed insight into current market dynamics and provides analysis on future market growth.
Favorable legislation in the market, policies across developed economies, and investments in the research and development for cannabis-infused drugs are the key factors responsible for the market growth.
Moreover, technological innovation to decide the accurate dose of cannabis-infused drugs with cutting edge delivery methods to ensure therapeutic and psychoactive events, to contain drug abuse among adults also favoring market growth for cannabis pharmaceuticals.
Blockchain technology in the pharmaceutical industry could be used to maintain strain purity and product formulations to have effective treatment for the therapeutic cause and will also enable us to capture dosage data for future considerations, thus technology could also play important role in shaping the market future of the cannabis pharmaceuticals industry.
In terms of product, the market is segmented into Epidiolex, Marinol, Cesamet, and Sativex.
CBD was discovered to be an excellent option for those who suffer from muscle spasms due to multiple sclerosis.
Cannabidiol, also called CBD, is the main ingredient in the drug that produces a calming effect on the human nervous system.
According to statistics that have been compiled, it is estimated that more than two million people in Canada alone suffer from symptoms of persistent and chronic muscle spasms that can be controlled with the help of medications.
Many people who suffer from muscle spasticity have found this information to be an advantage.A lot of people think that the benefits of medical marijuana are too significant to ignore.
The Medical Association of New Zealand has stated that cannabis has any medicinal value, yet many doctors in the country are still treating patients with this drug.
Despite numerous petitions being submitted at the federal level, and numerous discussions held at municipal or provincial levels, the cannabis plant remains illegal in a number of nations around the globe.Patients with debilitating conditions like epilepsy or cancer, HIV/AIDS, or other debilitating conditions cannot use medical marijuana.
